Latest Trials Latest NewsFAQ

Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Phase 2

Completed

Conditions: Small Cell Prostate Cancer
Neuroendocrine Prostate Cancer
Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers

Interventions: Drug: MLN8237

First Posted Date: 2013-02-26

Last Posted Date: 2018-01-23

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 60

Registration Number: NCT01799278

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

and more 5 locations

Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium

Phase 4

Conditions: Hepatic Fibrosis

Interventions: Procedure: MRI of liver

First Posted Date: 2013-02-04

Last Posted Date: 2013-02-04

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 40

Registration Number: NCT01783314

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery

Phase 4

Completed

Conditions: Lung Tumor

Interventions: Drug: Saline Placebo
Drug: IV Acetaminophen

First Posted Date: 2013-02-04

Last Posted Date: 2017-05-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 16

Registration Number: NCT01783236

Locations: 🇺🇸
Weill Cornell Medical College, New York City, New York, United States

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

Phase 2

Terminated

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Thalidomide
Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2013-01-30

Last Posted Date: 2018-07-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 4

Registration Number: NCT01779167

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Idiopathic Pulmonary Fibrosis (IPF)
Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Smoking Cessation
Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)
Smoking

First Posted Date: 2013-01-28

Last Posted Date: 2024-12-16

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 2000

Registration Number: NCT01776398

Locations: 🇺🇸
Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine, New York, New York, United States

Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection

Phase 1

Completed

Conditions: Brain Tumors With Ill-defined Margins

Interventions: Drug: Indigo carmine

First Posted Date: 2013-01-14

Last Posted Date: 2018-12-11

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 10

Registration Number: NCT01767415

Locations: 🇺🇸
Weill Cornell Medical College Department of Neurological Surgery, New York, New York, United States

Assessing Costs & Cost-variability Among Enrollees of Health Insurance Programs Utilizing Charlson's Comorbidity Index and Administrative Databases

Completed

Conditions: Multiple Chronic Illnesses

First Posted Date: 2013-01-04

Last Posted Date: 2017-02-20

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 241000

Registration Number: NCT01761253

Locations: 🇺🇸
Generations Plus/ Northern Manhattan Health Network, Bronx, New York, United States

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Phase 2

Terminated

Conditions: Myelofibrosis

Interventions: Drug: Peginterferon alfa-2a

First Posted Date: 2013-01-01

Last Posted Date: 2018-07-24

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 8

Registration Number: NCT01758588

Locations: 🇺🇸
Weill Medial College of Cornell Universiy, New York, New York, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Phase 2

Completed

Conditions: Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma
Distal Esophageal Adenocarcinoma

Interventions: Drug: Cabazitaxel

First Posted Date: 2012-12-28

Last Posted Date: 2018-04-03

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 85

Registration Number: NCT01757171

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

and more 2 locations

Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients

Not Applicable

Withdrawn

Conditions: Lung Cancer

Interventions: Radiation: Cs-131 brachytherapy seeds

First Posted Date: 2012-12-28

Last Posted Date: 2017-01-27

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT01757158

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy